Can-Fite BioPharma
(NYSE American: CANF) Webinar

The webinar is over.

Watch the webinar replay.

Watch our exclusive Can-Fite BioPharma webinar replay

Watch the Can-Fite BioPharma webinar replay.

Date: Monday, November 25, 2019 at 11:00 AM EST

Duration: 20+ mins

About Can-Fite BioPharma (NYSE American: CANF)

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction. The Company's lead drug candidate, Piclidenoson, is currently in Phase III trials for rheumatoid arthritis and psoriasis. Can-Fite's liver cancer drug, Namodenoson, recently completed a Phase II trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and is in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction in preclinical studies and the Company is investigating additional compounds, targeting A3AR, for the treatment of sexual dysfunction. These drugs have an excellent safety profile with experience in over 1,000 patients in clinical studies to date.

A live Q&A session, open to current and prospective investors, will immediately follow CEO Dr. Pnina Fishman's presentation.

For more information on Can-Fite BioPharma (NYSE American: CANF), visit

View investor deck